De Santis C, Siegel R, Bandi P, Jemal A (2011) Breast cancer statistics. Ca Cancer J Clin 61:409–18. https://doi.org/10.3322/caac.20134
DOI: 10.3322/caac.20134
Ferlay J, Colombet M, Soerjomataram I et al (2021) Cancer statistics for the year 2020: An overview. Int J Cancer.149(4):778–89. https://doi.org/10.1002/ijc.33588
DOI: 10.1002/ijc.33588
Agrawal S (2014) Late effects of cancer treatment in breast cancer survivors. South Asian J Cancer 3(2):112–5. https://dx.doi.org/10.4103%2F2278-330X.130445
DOI: 10.4103/2278-330X.130445
Liu J, Curtis EM, Cooper C, Harvey NC (2019) State of the art in osteoporosis risk assessment and treatment. J Endocrinol Invest 42(10):1149–64. https://doi.org/10.1007/s40618-019-01041-6
DOI: 10.1007/s40618-019-01041-6
Shapiro CL (2020) Osteoporosis: A long-term and late-effect of breast cancer treatments. Cancers (Basel) 12(11):1–17. https://dx.doi.org/10.3390%2Fcancers12113094
DOI: 10.3390/cancers12113094
Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145(4):247–54. https://doi.org/10.7326/0003-4819-145-4-200608150-00004
DOI: 10.7326/0003-4819-145-4-200608150-00004
Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function - Measured and estimated glomerular filtration rate. N Engl J Med 354(23):2473–83. https://doi.org/10.1056/nejmra054415
DOI: 10.1056/NEJMra054415
De La Piedra C, Traba M, Domínguez Cabrera C, Sosa-Henríquez M (1997) Biochemical markers of bone resorption in the study of postmenopausal osteoporosis. Clin Chim Acta 265:225–34. https://doi.org/10.1016/s0009-8981(97)00131-9
DOI: 10.1016/S0009-8981(97)00131-9
Domínguez Cabrera C, Sosa-Henríquez M, Traba M, Alvarez Villafañe E, De La Piedra C (1998) Biochemical markers bone formation in the study of postmenopausal osteoporosis. Osteoporos Int 8:147–51. https://doi.org/10.1007/bf02672511
DOI: 10.1007/BF02672511
Sosa M, Saavedra P, Muñoz-Torres M et al (2002) Quantitative ultrasound calcaneus measurements: Normative data and precision in the Spanish population. Osteoporos Int 13(6):487–92. https://doi.org/10.1007/s001980200059
DOI: 10.1007/s001980200059
Sosa M, Hernández D, Estévez S et al (1998) The range of bone mineral density in healthy canarian women by dual X-ray absorptiometry radiography and quantitative computer tomography. J Clin Densitom 4:385–93. https://doi.org/10.1385/jcd:1:4:385
DOI: 10.1385/JCD:1:4:385
Cano A, del Pino del Montes J, Del Rio-Barquero L et al (2017) Valores referencia TBS en población sana española de ambos sexos. Proyecto SEIOMM‐TBS. Rev Osteoporos Metab Miner Metab Min 9(3):5–7.
World Medical Association (2013) World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. JAMA 310(20):2013–6. https://doi.org/10.1001/jama.2013.281053
DOI: 10.1001/jama.2013.281053
Tenti S, Correale P, Cheleschi S, Fioravanti A, Pirtoli L (2020) Aromatase inhibitors—induced musculoskeletal disorders: Current knowledge on clinical and molecular aspects. Int J Mol Sci 21(16):1–38. https://doi.org/10.3390/ijms21165625
DOI: 10.3390/ijms21165625
Diana A, Carlino F, Giunta EF et al (2021) Cancer Treatment–Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. Curr Treat Options Oncol 22(5). https://doi.org/10.1007/s11864-021-00835-2
DOI: 10.1007/s11864-021-00835-2
Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, et al. Cancer-associated bone disease. Osteoporos Int. 2013;24(12):2929–53.
DOI: 10.1007/s00198-013-2530-3
Coleman RE, Body JJ, Gralow JR et al (2013) Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev. 2008;34(SUPPL. 1). https://doi.org/10.1007/s00198-013-2530-3
DOI: 10.1007/s00198-013-2530-3
Mariotti V, Page DB, Davydov O et al (2016) Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. J Bone Oncol 32–7. https://doi.org/10.1016/j.jbo.2016.10.004
DOI: 10.1016/j.jbo.2016.10.004
Martínez P, Galve E, Arrazubi V et al (2019) Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors. Reumatol Clin 15(4):211–7. https://doi.org/10.1016/j.reuma.2017.08.005
DOI: 10.1016/j.reuma.2017.08.005
Pant S, Shapiro CL (2008) Aromatase inhibitor-associated bone loss: Clinical considerations. Drugs 68(18):2591–600. https://doi.org/10.2165/0003495-200868180-00005
DOI: 10.2165/0003495-200868180-00005
Ramchand SK, Cheung YM, Grossmann M (2019)Bone health in women with breast cancer. Climacteric 22(6):589–95. https://doi.org/10.1080/13697137.2019.1580257
DOI: 10.1080/13697137.2019.1580257
Stratton J, Hu X, Soulos PR et al (2017) Bone density screening in postmenopausal women with early-stage breast cancer treated with aromatase inhibitors. J Oncol Pract 13(5):e505–13. https://doi.org/10.1200/jop.2016.018341
DOI: 10.1200/JOP.2016.018341
Zaman K, Thürlimann B, Huober J et al (2012) Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol 23(6):1474–81. https://doi.org/10.1093/annonc/mdr448
DOI: 10.1093/annonc/mdr448
Reid DM, Doughty J, Eastell R et al (2008) Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat Rev 34(SUPPL. 1). https://doi.org/10.1016/j.ctrv.2008.03.007
DOI: 10.1016/j.ctrv.2008.03.007
Rizzoli R, Body JJ, De Censi A, Reginster JY, Piscitelli P, Brandi ML (2012) Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: An ESCEO position paper. Osteoporos Int 23(11):2567–76. https://doi.org/10.1007/s00198-011-1870-0
DOI: 10.1007/s00198-011-1870-0
Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. Osteoporos Int. 1994;4(6):368–81. https://doi.org/10.1007/bf01622200
DOI: 10.1007/BF01622200
Clynes MA, Westbury LD, Dennison EM et al (2020) Bone densitometry worldwide: a global survey by the ISCD and IOF. Osteoporos Int 31(9):1779–86. https://doi.org/10.1007/s00198-020-05435-8
DOI: 10.1007/s00198-020-05435-8
Frost ML, Blake GM, Fogelman I (2001) Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res 16(2):406–16. https://doi.org/10.1359/jbmr.2001.16.2.406
DOI: 10.1359/jbmr.2001.16.2.406
Glüer CC, Cummings S, Bauer DC et al (1996) Osteoporosis: Association of recent fractures with Quantitative US findings. Radiology 199:725–32. https://doi.org/10.1148/radiology.199.3.8637996
DOI: 10.1148/radiology.199.3.8637996
Hans D, Durosier C, Kanis JA, Johansson H, Schott-Pethelaz AM, Krieg MA (2008) Assessment of the 10-year probability of osteoporotic hip fracture combining clinical risk factors and heel bone ultrasound: The EPISEM prospective cohort of 12,958 elderly women. J Bone Miner Res 23(7):1045–51. https://doi.org/10.1359/jbmr.080229
DOI: 10.1359/jbmr.080229
Maggi S, Noale M, Giannini S et al (2006) Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: The ESOPO study. Osteoporos Int 17(2):237–44. https://doi.org/10.1007/s00198-005-1985-2
DOI: 10.1007/s00198-005-1985-2
Glüer CC (2007) Quantitative Ultrasound-It is time to focus research efforts. Bone 40(1):9–13. https://doi.org/10.1016/j.bone.2006.07.014
DOI: 10.1016/j.bone.2006.07.014
Hans D, Fuerst T, Lang T et al (1997) How can we measure bone quality? Baillieres Clin Rheumatol 11(3):495–515. https://doi.org/10.1016/s0950-3579(97)80017-9
DOI: 10.1016/S0950-3579(97)80017-9
Wu C, Glüer C, Lu Y, Fuerst T, Hans D, Genant HK (1998) Ultrasound characterization of bone demineralization. Calcif Tissue Int 62(2):133–9. https://doi.org/10.1007/s002239900406
DOI: 10.1007/s002239900406
Glüer CC (2008) A new quality of bone ultrasound research. IEEE Trans Ultrason Ferroelectr Freq Control 55(7):1524–8. https://doi.org/10.1109/TUFFC.2008.828
DOI: 10.1109/TUFFC.2008.828
Catalano A, Gaudio A, Agostino RM, Morabito N, Bellone F, Lasco A (2019) Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors. J Endocrinol Invest 42(11):1337–43. https://doi.org/10.1007/s40618-019-01063-0
DOI: 10.1007/s40618-019-01063-0
Catalano A, Morabito N, Agostino RM et al (2017) Bone health assessment by quantitative ultrasound and dual-energy x-ray absorptiometry in postmenopausal women with breast cancer receiving aromatase inhibitors. Menopause 24(1):85–91.https://doi.org/10.1097/gme.0000000000000722
DOI: 10.1097/GME.0000000000000722
Harvey NC, Glüer CC, Binkley N et al (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 78:216–24. https://doi.org/10.1016/j.bone.2015.05.016
DOI: 10.1016/j.bone.2015.05.016
Del Rio LM, Winzenrieth R, Cormier C, Di Gregorio S (2013) Is bone microarchitecture status of the lumbar spine assessed by TBS related to femoral neck fracture? A Spanish case-control study. Osteoporos Int 24(3):991–8. https://doi.org/10.1007/s00198-012-2008-8
DOI: 10.1007/s00198-012-2008-8
Anderson KB, Holloway-Kew KL, Mohebbi M, Kotowicz MA, Hans D, Pasco JA (2018) Is trabecular bone score less affected by degenerative-changes at the spine than lumbar spine BMD? Arch Osteoporos 13(1). https://doi.org/10.1007/s11657-018-0544-3
DOI: 10.1007/s11657-018-0544-3